PANEL 4 · BIOTECHNOLOGY

A Biotechnology Hub

From idea to plan. From plan to practice?

Monday 23 November 2026 · 16:40–17:25Karatza Mansion, National Bank of Greece · 82-84 Aiolou St., Athens

The question mark in the title is not a typo. It is the panel’s question: how does a Greek biotechnology hub move from paper to the construction site?

Komvos’s initiative aims to build a mature scientific and technological base for the Life and Health Sciences economy. Its vehicle is a biotechnology industrial park, HeaL-SPRIT (Health and Life Sciences Park of Research, Industry and Training), whose first phase will bring together staff-training facilities, pharmaceutical production units and companies that redesign biotech production lines.

Its strategic partners are the ARISTEiA Institute (USA) and Accenture Greece. The first three stages of the feasibility study have been completed. The goal is for Greece to be among the EU countries leading the actions of the European Biotech Act. That is why the discussion brings together experts from every field, from research to production.

Topic: Biotechnology, biomedicine and applied research
Moderator: Lina Nikolopoulou — Managing Director, MindView, Strategy-Research eHealth Forum, Greece

SPEAKERS

Giorgos VardamidisQA Director – Biotechnology Operations, DEMO Pharmaceuticals, Greece
Konstantinos DrosatosCoordinator of the Komvos Biotechnology initiative/HeaL-SPRIT; Professor of Biomedical Sciences, University of Cincinnati College of Medicine, USA; Chair of the Board, ARISTEiA Institute, USA
Dafni BikaGlobal Head Pharmaceutical Technology and Development, AstraZeneca, USA
Fotis PanagiotopoulosManaging Director, Head of Strategy Consulting, Accenture Greece
Mata CharokopouR&D Portfolio Strategy Management Lead, Chief of Staff to Executive VP, Patient Evidence Unit, UCB, Belgium